Erucin, a Natural Isothiocyanate, Prevents Polyglutamine-Induced Toxicity in Caenorhabditis elegans via aak-2/AMPK and daf-16/FOXO Signaling

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Balducci, M
  • Tarozzi, A

Grupos

Abstract

Several neurodegenerative diseases (NDDs), such as Huntington's disease, six of the spinocerebellar ataxias, dentatorubral-pallidoluysian atrophy, and spinobulbar muscular atrophy, are caused by abnormally long polyglutamine (polyQ) tracts. Natural compounds capable of alleviating polyQ-induced toxicity are currently of great interest. In this work, we investigated the modulatory effect against polyQ neurotoxic aggregates exerted by erucin (ERN), an isothiocyanate naturally present in its precursor glucoerucin in rocket salad leaves and in its oxidized form, sulforaphane (SFN), in broccoli. Using C. elegans models expressing polyQ in different tissues, we demonstrated that ERN protects against polyQ-induced toxicity and that its action depends on the catalytic subunit of AMP-activated protein kinase (aak-2/AMPK alpha 2) and, downstream in this pathway, on the daf-16/FOXO transcription factor, since nematodes deficient in aak-2/AMPK alpha 2 and daf-16 did not respond to the treatment, respectively. Although triggered by a different source of neurotoxicity than polyQ diseases, i.e., by alpha-synuclein (alpha-syn) aggregates, Parkinson's disease (PD) was also considered in our study. Our results showed that ERN reduces alpha-syn aggregates and slightly improves the motility of worms. Therefore, further preclinical studies in mouse models of protein aggregation are justified and could provide insights into testing whether ERN could be a potential neuroprotective compound in humans.

Datos de la publicación

ISSN/ISSNe:
1661-6596, 1422-0067

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES  MDPI

Tipo:
Article
Páginas:
-
PubMed:
39596283
Factor de Impacto:
1,176 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 5

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • erucin; Caenorhabditis elegans; neuroprotection; polyQ toxicity; AMPK; daf-16/FOXO

Proyectos y Estudios Clínicos

Activación sinérgica de AMPK para detener el progreso de la enfermedad de Huntington

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

ACIF/2020/366 . CONSELLERIA DE EDUCACION . 2020

Modulating the activity of genes controlling fat metabolism as a therapeutic strategy in Huntington disease.

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

PI20/00114 . INSTITUTO DE SALUD CARLOS III . 2021

MODFAT-HD-Modulators of fat metabolism as druggable targets to treat Huntington Disease.

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

PCI2021-122099-2B . COMISION EUROPEA . 2022

Genes reguladores del metabolismo de las grasas como dianas terapéuticas contra la enfermedad de Huntington

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

CIACIF/2022/421 . CONSELLERIA DE INNOVACIÓN, UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL . 2023

Ubiquibodies, un recurso valioso para la eliminación de la proteína causante de la enfermedad de Huntington

Investigador Principal: ANDREA DEL VALLE CARRANZA FIGUEROA

CIACIF/2022/422 . CONSELLERIA DE INNOVACIÓN, UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL . 2023

Synergistic degradation of mutant huntingtin to treat Huntington disease, targeting enzymes of the lipid metabolism.

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

PI23/00455 . INSTITUTO DE SALUD CARLOS III . 2024

Cita

Compartir